psoriasis | pharmaphorum

Skip to main content

Wednesday 22 July 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

psoriasis

News

Escalier

Escalier raises $19m to fund novel psoriasis pill

Escalier Biosciences, a privately-held biopharma company based in The Netherlands, has raised $19 million to help advance its pipeline.

News

Novartis HQ

Novartis trumpets long-term data for Cosentyx in psoriasis

Novartis is hoping that new real world data will help its psoriasis drug Cosentyx stay ahead of rivals.

News

AbbVieHQ

AbbVie to file long-acting psoriasis contender

AbbVie hopes risankizumab will rebuild sales after Humira patent expires

News

Illustration of a nerve cell on a colored background with light effects

Bioelectronic wearable shows promise in psoriasis

Thync's bioelectronic wearable significantly reduced symptoms in psoriasis patients within four weeks of use.

News

J&J

J&J's psoriasis drug faces crowded market after US approval

J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.

News

Novartis HQ

Novartis' psoriasis drug gets label boost

New label shows Cosentyx is superior to J&J's rival in long-term.

Load more results

Editor's Picks

Novo's Wegovy pill cleared for weight loss in EU

Lilly buys into psychedelics with $3.8bn AtaiBeckley deal

Bayer's Kerendia on course for NHS use in heart failure

MSD gets first FDA okay for oral PCSK9 cholesterol drug

GSK abandons cough drug added in $2bn Bellus deal

News

Gilead, MSD share data on once-weekly oral HIV treatment

Gilead, MSD share data on once-weekly oral HIV treatment

Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company